<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795335</url>
  </required_header>
  <id_info>
    <org_study_id>KY2022-097-B</org_study_id>
    <nct_id>NCT05795335</nct_id>
  </id_info>
  <brief_title>CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer</brief_title>
  <official_title>Survival Outcomes, Adverse Events and Predictive Biomarkers for CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer, an Ambispective Single-center Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an ambispective, single-center study to evaluate the survival outcomes, adverse&#xD;
      events and predictive biomarkers for CDK4/6 inhibitors in patients with hormone&#xD;
      receptor-positive advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2023</start_date>
  <completion_date type="Anticipated">December 30, 2028</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>From the date of starting CDK4/6 inhibitor to the date of first documentation of progression or death (up to approximately 2.5 years)</time_frame>
    <description>PFS is defined as the time from the date of starting CDK4/6 inhibitor to the date of objective tumor progression as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) or death from any cause in the absence of documented PD, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of starting CDK4/6 inhibitor until death from any cause up to 3 years</time_frame>
    <description>Overall survival is defined as the time from starting CDK4/6 inhibitor to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From the date of starting CDK4/6 inhibitor to the end of the treatment (up to approximately 2.5 years)</time_frame>
    <description>Adverse events during CDK4/6 regimen will be assessed according to the NCI CTCAE v5.0.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patients have received or plan to receive CDK4/6 inhibitors for advanced disease.</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDK4/6 inhibitor</intervention_name>
    <description>CDK4/6 inhibitors</description>
    <arm_group_label>Patients have received or plan to receive CDK4/6 inhibitors for advanced disease.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hormone receptor-positive breast cancer patients who have received or plan to receive&#xD;
        CDK4/6 inhibitors for advanced disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged â‰¥18 and older&#xD;
&#xD;
          -  Confirmed diagnosis of hormone receptor-positive breast cancer.&#xD;
&#xD;
          -  Subjects with locoregionally recurrent or metastatic disease not amenable to curative&#xD;
             therapy.&#xD;
&#xD;
          -  Subjects have received or plan to receive CDK4/6 inhibitors for advanced disease.&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects disable to swallow pills.&#xD;
&#xD;
          -  History of immunodeficiency disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ziping Wu, MD</last_name>
    <phone>86(21)68385569</phone>
    <email>wuziping@renji.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qi Lu</last_name>
    <phone>86(21)68383364</phone>
    <email>rjllb3364@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Renji Hospital, School of Medicine, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>jinsong Lu, MD</last_name>
      <email>lujingsong@renji.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 21, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>April 5, 2023</last_update_submitted>
  <last_update_submitted_qc>April 5, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Jinsong Lu</investigator_full_name>
    <investigator_title>Jinsong Lu, Chief of Breast Surgery Department, RenJi Hospital</investigator_title>
  </responsible_party>
  <keyword>Locoregionally Recurrent</keyword>
  <keyword>Metastatic</keyword>
  <keyword>CDK4/6 Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

